The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Henry Ford Health System
Study ID
NCT04233749
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Ashy Dermatosis of Ramirez
  • Erythema Dyschromicum Perstans
  • Lichen Planus Pigmentosus

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tranexamic acid tablets — DRUG
    325mg of tranexamic acid twice daily for six months

Study Details

There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder. Given that LPP, EDP, and melasma are all disorders of pigmentation with dermal involvement, it is possible that tranexamic acid can also reduce pigmentation in LPP and EDP as well.

Key Dates

Start date
Mar 17, 2020
Status verified
Sep 2025
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025

Study Design

Enrollment
5 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    All five subjects will receive tranexamic acid tablets, 325mg twice daily for six months.

Primary Outcome Measure

Change in Pigmentation using Colorimetry [ Time Frame: 11 visits over 270 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
New Center OneDetroitMichigan48202
Jennifer Creasor, RN
[email protected]

Find similar trials in Detroit, MI

By research site
New Center One· Detroit, MI